TORL Biotherapeutics, LLC on LinkedIn: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2…

TORL Biotherapeutics, LLC’s Post

1,862 followers

6mo

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

5 Comments

6mo

Congratulations to the TORL team bringing UCLA therapies to the market.

Project Management/CMC Management

6mo

Congratulations to the TORL Team!

Sales Leader/Healthcare/Technology/Key Accounts

6mo

Congrats Team TORL!

Director of Strategic Initiatives at Leaderboard Branding

6mo

Congratulations to the TORL BioTherapeutics Team!